AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

Amgen’s Otezla was the subject of a spoof pharma ad that ran during SNL’s most recent episode. The ad, featuring actor Ryan Gosling, poked fun at the supposed mystery behind the medication and its ...

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Skyrizi is a prescription drug used to treat certain autoimmune conditions, such as Crohn’s disease, in adults. There are currently no known interactions between Skyrizi and other medications, alcohol ...

NORTH CHICAGO, Ill., June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI ®, 180 mg or ...

It’s not known whether Skyrizi, which doctors prescribe to treat inflammatory bowel disease (IBD) and other conditions, is a safe treatment option during pregnancy or breastfeeding. However, IBD can ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Belgium’s largest drugmaker UCB has announced positive topline data from the BE BOLD trial assessing Bimzelx bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis ...

AbbVie ABBV announced that its key drug, Skyrizi (risankizumab) met all primary and secondary endpoints of a head-to-head phase III study comparing the drug against J&J’s JNJ blockbuster medicine, ...